Source: Google NewsPublished on 2021-02-18
Related Articles:
- The Anavex results June 29, 2021 # # # # This week some encouraging clinical trial results were announced by a biotech firm called Anavex Life Sciences. The company had been testing their lead experimental therapy – a Sigma-1 receptor agonist called ANAVEX2-73 (also known as blarcamesine) – in 132 people with Parkinson’s disease dementia over a 14 week period. The results are rather encouraging: significantly…
- Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021 - StreetInsider.com February 18, 2021 Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021 StreetInsider.com
- The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s. It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
- Sio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare Conference - GlobeNewswire February 16, 2021 Sio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
- Parkinson’s Dementia Trial of Oral Anavex 2-73 to Continue with Adjustments April 3, 2020 Anavex Life Sciences announced plans to continue to screen and enroll patients into its active trials for Alzheimer’s disease and Rett syndrome, in accordance to institutional rules and government guidance related to the COVID-19 pandemic. A Phase 2 study of people with dementia linked to Parkinson’s disease is fully enrolled, and the company expects to announce topline results by June. Contingency plans are…
- Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021 - Yahoo Finance February 18, 2021 Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021 Yahoo Finance
- AC Immune to Present at the SVB Leerink 11th Annual Global - GlobeNewswire February 2, 2022 AC Immune to Present at the SVB Leerink 11th Annual Global GlobeNewswire
- Anavex Life Sciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference - Yahoo Finance February 10, 2022 Anavex Life Sciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference Yahoo Finance
- Monthly Research Review – February 2021 February 28, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2021. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news…
- Monthly Research Review – February 2022 February 28, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2022. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
- Sio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare Conference - Yahoo Finance February 16, 2021 Sio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare Conference Yahoo Finance
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
- Adamas to Present at Upcoming SVB Leerink CNS Forum - Business Wire June 23, 2021 Adamas to Present at Upcoming SVB Leerink CNS Forum Business Wire
- Monthly Research Review – January 2021 January 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during the previous 4 weeks. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical…
- Monthly Research Review: Jaunary 2020 January 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2020. The post is divided into seven parts based on the type of research: Basic biology, Disease mechanism, Clinical research, New clinical trials, Clinical trial news, Other news, and…
- Monthly Research Review – June 2021 June 30, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during June 2021. The post is divided into 10 parts based on the type of research: Top 4 pieces of Parkinson’s news Articles of general interest Basic biology…
- Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer's Disease - BioSpace June 14, 2021 Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer's Disease BioSpace
- Monthly research review: February 2020 February 29, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Year in review: 2021 December 31, 2021 # # # # As with the preceding year, 2021 proved to be challenging due to the continuing COVID-19 pandemic (and it is not over yet). Vaccines were rolled out with remarkable speed, but equally new variants of the virus popped up and have kept Governments and health regulatory bodies on their toes. An amazing feature of the last two…
- Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from ANAVEX®2-73-PDD-001 Parkinson's Disease Dementia Study at AD/PD™ 2022 International Conference - Marketscreener.com March 15, 2022 Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from ANAVEX®2-73-PDD-001 Parkinson's Disease Dementia Study at AD/PD™ 2022 International Conference Marketscreener.com
- Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 - GlobeNewswire June 14, 2021 Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 GlobeNewswire